290 related articles for article (PubMed ID: 31388770)
1. DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome.
Birnbaum Y; Tran D; Bajaj M; Ye Y
Basic Res Cardiol; 2019 Aug; 114(5):35. PubMed ID: 31388770
[TBL] [Abstract][Full Text] [Related]
2. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
[TBL] [Abstract][Full Text] [Related]
3. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y; Bajaj M; Yang HC; Ye Y
Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
[TBL] [Abstract][Full Text] [Related]
5. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together.
Wang X; Ding Z; Yang F; Dai Y; Chen P; Theus S; Singh S; Budhiraja M; Mehta JL
Clin Sci (Lond); 2016 Aug; 130(15):1353-62. PubMed ID: 27129181
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.
Aroor AR; Habibi J; Kandikattu HK; Garro-Kacher M; Barron B; Chen D; Hayden MR; Whaley-Connell A; Bender SB; Klein T; Padilla J; Sowers JR; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2017 May; 16(1):61. PubMed ID: 28476142
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
[TBL] [Abstract][Full Text] [Related]
8. Cathelicidin aggravates myocardial ischemia/reperfusion injury via activating TLR4 signaling and P2X
Wu Y; Zhang Y; Zhang J; Zhai T; Hu J; Luo H; Zhou H; Zhang Q; Zhou Z; Liu F
J Mol Cell Cardiol; 2020 Feb; 139():75-86. PubMed ID: 31982429
[TBL] [Abstract][Full Text] [Related]
9. Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy.
Jo CH; Kim S; Park JS; Kim GH
Kidney Blood Press Res; 2018; 43(3):987-999. PubMed ID: 29913457
[TBL] [Abstract][Full Text] [Related]
10. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
[TBL] [Abstract][Full Text] [Related]
11. Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice.
Yu Y; Chen D; Zhao Y; Zhu J; Dong X
Int J Immunopathol Pharmacol; 2021; 35():20587384211036819. PubMed ID: 34399601
[TBL] [Abstract][Full Text] [Related]
12. Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart.
Fender AC; Kleeschulte S; Stolte S; Leineweber K; Kamler M; Bode J; Li N; Dobrev D
Basic Res Cardiol; 2020 Jan; 115(2):10. PubMed ID: 31912235
[TBL] [Abstract][Full Text] [Related]
13. Alcohol-induced IL-1β in the brain is mediated by NLRP3/ASC inflammasome activation that amplifies neuroinflammation.
Lippai D; Bala S; Petrasek J; Csak T; Levin I; Kurt-Jones EA; Szabo G
J Leukoc Biol; 2013 Jul; 94(1):171-82. PubMed ID: 23625200
[TBL] [Abstract][Full Text] [Related]
14. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury.
Sandanger Ø; Ranheim T; Vinge LE; Bliksøen M; Alfsnes K; Finsen AV; Dahl CP; Askevold ET; Florholmen G; Christensen G; Fitzgerald KA; Lien E; Valen G; Espevik T; Aukrust P; Yndestad A
Cardiovasc Res; 2013 Jul; 99(1):164-74. PubMed ID: 23580606
[TBL] [Abstract][Full Text] [Related]
15. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Sauvé M; Ban K; Momen MA; Zhou YQ; Henkelman RM; Husain M; Drucker DJ
Diabetes; 2010 Apr; 59(4):1063-73. PubMed ID: 20097729
[TBL] [Abstract][Full Text] [Related]
16. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway.
Dai Y; Dai D; Wang X; Ding Z; Mehta JL
Cardiovasc Drugs Ther; 2014 Oct; 28(5):425-32. PubMed ID: 25022544
[TBL] [Abstract][Full Text] [Related]
17. Visfatin/eNampt induces endothelial dysfunction in vivo: a role for Toll-Like Receptor 4 and NLRP3 inflammasome.
Romacho T; Valencia I; Ramos-González M; Vallejo S; López-Esteban M; Lorenzo O; Cannata P; Romero A; San Hipólito-Luengo A; Gómez-Cerezo JF; Peiró C; Sánchez-Ferrer CF
Sci Rep; 2020 Mar; 10(1):5386. PubMed ID: 32214150
[TBL] [Abstract][Full Text] [Related]
18. Wu-Mei-wan protects pancreatic β cells by inhibiting NLRP3 Inflammasome activation in diabetic mice.
Yang X; Lu F; Li L; Li J; Luo J; Zhang S; Liu X; Chen G
BMC Complement Altern Med; 2019 Jan; 19(1):35. PubMed ID: 30704457
[TBL] [Abstract][Full Text] [Related]
19. Carbon monoxide releasing molecule-3 improves myocardial function in mice with sepsis by inhibiting NLRP3 inflammasome activation in cardiac fibroblasts.
Zhang W; Tao A; Lan T; Cepinskas G; Kao R; Martin CM; Rui T
Basic Res Cardiol; 2017 Mar; 112(2):16. PubMed ID: 28168403
[TBL] [Abstract][Full Text] [Related]
20. Lipopolysaccharide (LPS) Aggravates High Glucose- and Hypoxia/Reoxygenation-Induced Injury through Activating ROS-Dependent NLRP3 Inflammasome-Mediated Pyroptosis in H9C2 Cardiomyocytes.
Qiu Z; He Y; Ming H; Lei S; Leng Y; Xia ZY
J Diabetes Res; 2019; 2019():8151836. PubMed ID: 30911553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
